SB 49: RELATING TO TERMINAL ILLNESSES.

Session Year: 2025-2026
House: Senate

Current Status:

In Progress

(2025-12-08: Carried over to 2026 Regular Session.)

Introduced

First Committee Review

First Chamber

Second Committee Review

Second Chamber

Final Decking

Enacted

Version:

Authorizes manufacturers of investigational drugs or biological products that are pending approval by the United States Food and Drug Administration to make the drugs or products available to terminally ill patients under certain conditions. Effective 1/1/2026.

Discussed in Hearing

Senate Standing Committee on Health and Human Services

Jan 29, 2025

Senate Standing Committee on Health and Human Services

View Older Hearings

News Coverage:

SB 49: RELATING TO TERMINAL ILLNESSES. | Digital Democracy